On the recordNovember 18, 2013
I now ask unanimous consent that the cloture motion with respect to H.R. 3204, the pharmaceutical drug compounding bill, be withdrawn, the pending motion and amendments be withdrawn, and the Senate vote on the passage of the bill. The PRESIDING OFFICER (Mr. Kaine). Without objection, it is so ordered. The bill (H.R. 3204) was ordered to a third reading and was read the third time. Animal Drug Compounding <bullet> Mr. ISAKSON. Mr. President, I wish to thank Mr. Alexander for his work on this legislation. I am happy to see that all sides have been able to reach an agreement on clarifying the oversight of large compounding facilities, while also ensuring that patients continue to have access to customized medicines at their local pharmacy. I am grateful to the chairman and ranking member for clarifying that the intent of this legislation is to maintain current law with respect to patients' and physicians' access to drugs compounded for office use. I am also very encouraged that we are finally moving forward on creating a uniform national standard for the pharmaceutical supply chain, which will allow patients to have more confidence in the safety of the drugs they receive while also ensuring that national distributors and third- party logistics providers do not face the burden of dealing with a confusing and inconsistent patchwork of State-by-State rules. I would like to take a moment to discuss an issue that is not directly addressed in the bill before us.…





